ATE269064T1 - Impfstoffe gegen den hepatitis b und c virus - Google Patents

Impfstoffe gegen den hepatitis b und c virus

Info

Publication number
ATE269064T1
ATE269064T1 AT95938824T AT95938824T ATE269064T1 AT E269064 T1 ATE269064 T1 AT E269064T1 AT 95938824 T AT95938824 T AT 95938824T AT 95938824 T AT95938824 T AT 95938824T AT E269064 T1 ATE269064 T1 AT E269064T1
Authority
AT
Austria
Prior art keywords
hepatitis
viral genome
virus
disclosed
incomplete
Prior art date
Application number
AT95938824T
Other languages
English (en)
Inventor
Catherine J Pachuk
Jack Wands
Takaji Wakita
Vincent R Zurawski Jr
Leslie R Coney
Katsutoshi Tokushige
Original Assignee
Apollon Inc
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26981379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE269064(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apollon Inc, Massachusetts Gen Hospital filed Critical Apollon Inc
Application granted granted Critical
Publication of ATE269064T1 publication Critical patent/ATE269064T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT95938824T 1994-10-05 1995-10-05 Impfstoffe gegen den hepatitis b und c virus ATE269064T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31824894A 1994-10-05 1994-10-05
US46785995A 1995-06-06 1995-06-06
PCT/US1995/013552 WO1996010997A1 (en) 1994-10-05 1995-10-05 Hepatitis virus vaccines

Publications (1)

Publication Number Publication Date
ATE269064T1 true ATE269064T1 (de) 2004-07-15

Family

ID=26981379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95938824T ATE269064T1 (de) 1994-10-05 1995-10-05 Impfstoffe gegen den hepatitis b und c virus

Country Status (9)

Country Link
EP (1) EP0789563B8 (de)
JP (1) JPH11501204A (de)
AT (1) ATE269064T1 (de)
AU (1) AU701747B2 (de)
CA (1) CA2202088A1 (de)
DE (1) DE69533167D1 (de)
HU (1) HUT77870A (de)
NZ (1) NZ296304A (de)
WO (1) WO1996010997A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU717542B2 (en) 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
JP2002125688A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｃ型肝炎ウイルスの高感度検出のためのオリゴヌクレオチドおよび検出法
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2055149A1 (en) * 1990-11-08 1992-05-09 Hiroaki Okamoto Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides
JPH0692996A (ja) * 1991-12-28 1994-04-05 Kunitada Shimotoono Ｃ型肝炎ウィルス粒子を構成する蛋白質およびその発現
JP3439209B2 (ja) * 1992-01-31 2003-08-25 アボツト・ラボラトリーズ Ｈｃｖ蛋白のための哺乳動物発現システム
JPH07503615A (ja) * 1992-02-04 1995-04-20 カイロン　コーポレイション 肝炎療剤
JPH06141870A (ja) * 1992-03-12 1994-05-24 Tokyo Met Gov Rinshiyou Igaku Sogo Kenkyusho 非ａ非ｂ型肝炎ウイルス抗原をコードするｄｎａ断片
JPH06279500A (ja) * 1992-09-30 1994-10-04 Imuno Japan:Kk ＨＢｃ融合蛋白粒子およびその製造方法

Also Published As

Publication number Publication date
HUT77870A (hu) 1998-09-28
EP0789563B8 (de) 2004-11-17
JPH11501204A (ja) 1999-02-02
EP0789563A4 (de) 1998-10-07
WO1996010997A1 (en) 1996-04-18
CA2202088A1 (en) 1996-04-18
AU4006195A (en) 1996-05-02
EP0789563B1 (de) 2004-06-16
NZ296304A (en) 1999-06-29
AU701747B2 (en) 1999-02-04
DE69533167D1 (de) 2004-07-22
EP0789563A1 (de) 1997-08-20

Similar Documents

Publication Publication Date Title
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
ATE369384T1 (de) Expression und export von interferon-alpha proteinen als fc fusionsproteine
YU37502A (sh) Infektivni klonovi
DE69837708D1 (de) Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion
EP1054683A4 (de) Modifizierter hitzeschockprotein/peptidantigen komplex
RU2003118436A (ru) Модифицированный вариант вируса коровьей оспы ankara
SI2338508T1 (en) The recombinant chimeric dengue rENEN3 / 4delta 30 (ME), rDEN2 / 4delta30 (ME), or rDEN1 / 4delta30 (ME) dengue rDEN3 / 4delta30 (ME), containing deletion 30 of nucleotides (delta30) in part 3 of the untranslated genome dengue type 4, wherein deletion 30 nucleotides corresponds to the structure of the stem-loop TL2
ATE309367T1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
CN119421716A (zh) 用于环状rna亲和纯化的组合物和方法
DE69533167D1 (de) Impfstoffe gegen den hepatitis b und c virus
Palese et al. Structure, Genetic structure and genetic variation of influenza viruses
DE69626681D1 (de) Konditionell-replizierende virale vektoren und ihre verwendung.
CU23245A1 (es) CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
BR9508645A (pt) Vacina da peritonite infecciosa felina
BR9908540A (pt) Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c
RU97107000A (ru) Вакцины против вирусов гепатита
Morrison mRNA Vaccines and their impact on medicine.
TH63069A (th) โคลนก่อการติดเชื้อ
PT1254663E (pt) Agente antiviral
RU93018105A (ru) Штамм рекомбинантного вируса осповакцины, вызывающий иммунитет против вируса венесуэльского энцефаломиелита лошадей в организме животных, и способ его получения
RU2346044C2 (ru) ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-gp140(A)-hum
US20040001805A1 (en) Method and compositions for conferring viral immunity and reversing viral pathogenesis via strategic infection with a theravirus thereby providing genomic integration of genetically engineered, replication incompetent, integrating viral DNA
TH1348A (th) การประดิษฐ์ไวรัสที่มีโปรตีนพื้นผิวเป็นรีคอมบิแนนท์?โปรตีน
TH59474A (th) รีคอมบิแนนท์ไวรัสที่สามารถถอดแบบได้และวิธีใช้งานของมัน

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties